Various G-CSF Regimens to Prevent Infection During Chemotherapy
Primary G-CSF Prophylaxis During the First Two Cycles Only or Throughout All Chemotherapy Cycles in Breast Cancer Patients at Risk of Febrile Neutropenia
Sponsor: Academisch Ziekenhuis Maastricht
Listed as NCT00536081, this PHASE3 trial focuses on Breast Cancer and Chemotherapy and remains completed. Sponsored by Academisch Ziekenhuis Maastricht, it has been updated 9 times since 2008, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Dec 2019 — Jan 2021 [monthly]
Completed PHASE3
Status: Terminated → Completed
▶ Show 4 earlier versions
-
Jun 2018 — Dec 2019 [monthly]
Terminated PHASE3
-
May 2018 — Jun 2018 [monthly]
Terminated PHASE3
-
Aug 2017 — May 2018 [monthly]
Terminated PHASE3
-
Jan 2017 — Aug 2017 [monthly]
Terminated PHASE3
First recorded
Jan 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Academisch Ziekenhuis Maastricht
- ZonMw: The Netherlands Organisation for Health Research and Development
For direct contact, visit the study record on ClinicalTrials.gov .